Company news

GT Biopharma, Inc. news in 2026

GT Biopharma, Inc.'s news releases, calls and decks from 2026, newest first.

View company

GT Biopharma Selected for Oral Presentation at the SITC 2026 Annual Meeting

October 26, 2026

GT Biopharma Announces Potential New Indication for GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager, for Multiple Myeloma

September 15, 2026

GT Biopharma to Host Live Company Presentation on the Development of TriKE® Platform for Cancer Treatment, September 11, 2026

September 11, 2026

GT Biopharma Reports Second Quarter 2026 Financial Results

August 14, 2026

Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet

June 7, 2026

GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives

June 1, 2026

GT Biopharma Reports First Quarter 2026 Financial Results

May 15, 2026

GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors

May 13, 2026

GT Biopharma to Participate in the 38th Annual Roth Conference

March 11, 2026

Amendment to Quarterly Report (Form 10-Q/A)

March 6, 2026

GT Biopharma Reports Full Year 2025 Financial Results

March 1, 2026

GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference

February 17, 2026

GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3

February 3, 2026

GT Biopharma Announces IND Submission for GTB-5550 TriKE, a B7-H3-targeted natural killer cell engager for B7-H3 expressing solid tumor cancers

January 16, 2026

GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers

January 15, 2026

Decks in 2026